Skip to main content
OpenTrials
Completed

NCT Number: NCT01185262

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia

The rationale for combining lenalidomide with rituximab derives from preclinical observations suggesting that lenalidomide may enhance the ADCC (antigen-dependent cellular cytotoxicity) triggered by monoclonal antibodies such as rituximab. Lenalidomide augments NK cytotoxicity by increasing CD56dimCD3 subset, in addition to inducing IL-2 in T cells. These results provide the cellular and molecular basis for the use of lenalidomide as an adjuvant in immunotherapeutic strategies of monoclonal antibodies (mAb)-based therapies. The combination lenalidomide-rituximab was tested in lymphoma cell lines but not specifically on CLL cell lines. However the observed synergism was attributed to NK cells expansion, thus lending support to the notion that this synergism may operate in other B-cell lymphoproliferative malignancies.

The objective was to develop a non-cytotoxic and effective treatment for CLL that would fulfill an unmet medical need, as a significant proportion of CLL patients are elderly and frail. These patients experience an excess in chemotherapy induced toxicity, often preventing the completion of the planned treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Lymphocytic Leukemia Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Hospital Universitario Reina Sofía, Córdoba, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recurrent and refractory CLL patients that have received at least one previous treatment with purine analogs.
  • Adequate liver function and renal function.
  • ECOG performance status ≤ 2.
  • Signed informed consent
  • Male and female patients who are fertile agree to use an effective barrier method of birth control to avoid pregnancy.

Exclusion criteria

  • Positive serological markers for hepatitis B with the exception of HBsAc in previously vaccinated patients
  • Pregnant patients
  • HIV infection
  • Concurrent chemotherapy or immunotherapy
  • Other malignancy within the last 2 years, except for localized cutaneous carcinoma
  • Neurological impairment precluding understanding of protocol and the entailed visits and procedures.
  • Patients with Renal insufficiency that requires dialysis.

Treatment and study plan

Lenalidomida and Rituximab

Drug

Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.

Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).

In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.

If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).

In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1.

Other names: Lenalidomide: REVLIMID, Rituximab: MABTHERA

Primary outcomes

  1. Phase I: To determine Starting Recommended Dose for the first cycle and the subsequent cycles (Maximal Tolerated Dose)in relapsed B-cell CLL patients.

    Time frame: 5 months

    6 treatment cycles followed by an evaluation visit (between 60-90 days after last dosing) and quarterly follow up visits, until disease progression. Module I: patients on every cohort will have the same dose during treatment, except if they experiment DLT, in which case dose will be decreased (unless they are on the first dose level).

Secondary outcomes

  1. To determine the toxicity profile of LenRtx.

    Time frame: 5 months

    Phase II: patients will be followed during 6 cycles, safety assessment visit and quarterly follow up visits

  2. To determine the time to treatment failure.

    Time frame: 5 months

    Phase II: patients will be followed during 6 cycles, safety assessment visit and quarterly follow up visits

  3. To determine the molecular response rate.

    Time frame: 5 months

    Phase II: patients will be followed during 6 cycles, safety assessment visit and quarterly follow up visits

  4. To determine the clinical response rate (combined morphological and flow cytometry criteria).

    Time frame: 5 months

    6 treatment cycles followed by an evaluation visit (between 60-90 days after last dosing) and quarterly follow up visits, until disease progression

Sponsors and collaborators

Lead sponsor

MD Anderson International Spain SA

Other

Collaborators

  • Celgene Corporation

Registry information

Official study title

Phase I Study of the Activity and Safety of Lenalidomide and Rituximab as Non-chemotherapy Therapy for Patients With Recurrent and Refractory Chronic Lymphocytic Leukemia

Acronym: LLC-LENAR-08

Important dates

Study start
2009
Primary completion
2012
Study completion
2013
First posted
Aug 19, 2010
Registry last updated
Sep 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.